Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer
- 1 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (9), 2746-2757
- https://doi.org/10.1158/1535-7163.mct-08-0177
Abstract
Gene chip and proteomic analyses of tumors and stromal tissue has led to the identification of dozens of candidate tumor and host components potentially involved in tumor-stromal interactions, angiogenesis, and progression of invasive disease. In particular, matrix metalloproteases (MMP) have emerged as important biomarkers and prognostic factors for invasive and metastatic cancers. From an initial screen of benign versus malignant patient fluids, we delineated a metalloprotease cascade comprising MMP-14, MMP-9, and MMP-1 that culminates in activation of PAR1, a G protein-coupled protease-activated receptor up-regulated in diverse cancers. In xenograft models of advanced peritoneal ovarian cancer, PAR1-dependent angiogenesis, ascites formation, and metastasis were effectively inhibited by i.p. administration of cell-penetrating pepducins based on the intracellular loops of PAR1. These data provide an in vivo proof-of-concept that targeting the metalloprotease-PAR1 signaling system may be a novel therapeutic approach in the treatment of ovarian cancer. [Mol Cancer Ther 2008;7(9):2746–57]Keywords
Other Versions
This publication has 51 references indexed in Scilit:
- 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damageNature Immunology, 2007
- A cancer cell metalloprotease triad regulates the basement membrane transmigration programGenes & Development, 2006
- Pharmacology and In Vivo Efficacy of Pepducins in Hemostasis and Arterial ThrombosisPublished by Informa UK Limited ,2006
- Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysisNature Medicine, 2005
- Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal DisseminationClinical Cancer Research, 2005
- Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID miceGynecologic Oncology, 2004
- Differential Actions of PAR 2 and PAR 1 in Stimulating Human Endothelial Cell Exocytosis and PermeabilityCirculation Research, 2003
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Differential Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Protein and mRNA in Epithelial Ovarian TumorsGynecologic Oncology, 2000